1. Home
  2. ARCT vs OMER Comparison

ARCT vs OMER Comparison

Compare ARCT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcturus Therapeutics Holdings Inc.

ARCT

Arcturus Therapeutics Holdings Inc.

N/A

Current Price

$15.98

Market Cap

163.4M

Sector

Health Care

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$17.60

Market Cap

844.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ARCT
OMER
Founded
2013
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
163.4M
844.6M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
ARCT
OMER
Price
$15.98
$17.60
Analyst Decision
Buy
Strong Buy
Analyst Count
10
5
Target Price
$24.11
$32.50
AVG Volume (30 Days)
1.4M
1.4M
Earning Date
05-07-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
98.15
EPS
N/A
0.77
Revenue
$82,031,000.00
$29,868,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$12.77
$233.22
P/E Ratio
N/A
$22.89
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$3.94
52 Week High
$24.14
$19.65

Technical Indicators

Market Signals
Indicator
ARCT
OMER
Relative Strength Index (RSI) 65.93 49.27
Support Level $6.47 $10.16
Resistance Level $17.75 $17.65
Average True Range (ATR) 1.37 0.82
MACD -0.24 -0.45
Stochastic Oscillator 58.75 21.47

Price Performance

Historical Comparison
ARCT
OMER

About ARCT Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

Share on Social Networks: